Company

Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion

CompanyDrug

BMS’s Azacitidine, First Oral AML Therapy, Reaches GBA Patients via Special Policy

CompanyDrug

Abbisko Therapeutics Reports Positive Phase I Results for ABSK061 in Solid Tumors at ESMO TAT 2024

CompanyDrug

Cutia Therapeutic’s CU-20401 Shows Promising Safety and Efficacy in Phase I Abdominal Fat Reduction Study

CompanyDrug

Shandong Buchang Pharmaceuticals Gets NMPA Greenlight for Phase I Study of BC001 in Solid Tumors

CompanyDrug

Bayer’s BAY 2927088 Receives FDA Breakthrough Therapy Designation for HER2-Mutated NSCLC

CompanyDrug

Haisco Pharmaceutical Gets NMPA Greenlight for HSK39775 Solid Tumor Drug Candidate

CompanyDrug

Gilead’s Biktarvy Receives FDA Approval for Expanded HIV Treatment Indication

Company

Zai Lab Ltd Reports 31% YOY Growth in Product Revenues and Strategic Pipeline Expansion

CompanyDeals

Harbour BioMed Partners with Boostimmune to Develop Novel ADC Therapies

Policy / Regulatory

China’s NMPA Updates Rules for Administrative Penalty Discretions in Drug Supervision

CompanyDrug

AstraZeneca’s Fasenra Matches Nucala in EGPA Trial and Shows Steroid Reduction Benefits